Humira vs Rinvoq
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| CA Humira | CA Rinvoq | |
|---|---|---|
| Generic name | adalimumab | upadacitinib |
| Drug class | TNF Inhibitor (Biologic) | JAK Inhibitor |
| Treats | Rheumatoid arthritis, psoriasis, Crohn's disease | Rheumatoid arthritis, psoriatic arthritis, eczema |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | AbbVie |
| Year approved | 2002 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $95M | $38M |
| Common side effects | Serious infections, Increased cancer risk, Allergic reactions, Injection site reactions | Serious infections, Blood clots, Cardiovascular events, Cancer risk |
Frequently asked questions
Is Humira or Rinvoq better?
Neither is universally "better." Humira (adalimumab) and Rinvoq (upadacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Humira and Rinvoq?
Humira is a TNF Inhibitor (Biologic) made by AbbVie, while Rinvoq is a JAK Inhibitor made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Humira has the larger estimated TV advertising budget of the two.